Literature DB >> 8380143

Localization of DNA topoisomerase II in Chinese hamster fibroblasts by confocal and electron microscopy.

P Petrov1, F H Drake, A Loranger, W Huang, R Hancock.   

Abstract

The localization of the 170- and the 180-kDa isoforms of the enzyme DNA topoisomerase II in growing Chinese hamster fibroblasts has been studied by confocal immunofluorescence microscopy and immunogold electron microscopy after labeling with affinity-purified isoform-specific polyclonal antibodies. Immunofluorescence and immunogold studies, together with quantitative image analysis, show that the two isoforms are present in the nucleoplasm and in the nucleolus. In the nucleoplasm both isoforms are frequently localized at the periphery of heterochromatin regions. In the nucleolus the immunofluorescence and immunogold signals relative to surface area are higher than in the nucleoplasm; both isoforms are localized predominantly in the fibrillar zones. During mitosis both isoforms remain detectable in the cytoplasm. The differential expression of the two isoforms during the cell cycle, observed in other studies, suggests that they have different functions, and their presence in both the nucleoplasm and the nucleolus suggests that these functions are required in both of these nuclear compartments.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380143     DOI: 10.1006/excr.1993.1010

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  12 in total

1.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

Authors:  F Boege; A Andersen; S Jensen; R Zeidler; H Kreipe
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

2.  The distribution of topoisomerase II on mammalian chromosomes.

Authors:  A T Sumner
Journal:  Chromosome Res       Date:  1996-01       Impact factor: 5.239

3.  Organization of DNA topoisomerase II isotypes during the cell cycle of human lymphocytes and HeLa cells.

Authors:  N Chaly; X Chen; J Dentry; D L Brown
Journal:  Chromosome Res       Date:  1996-09       Impact factor: 5.239

4.  Human DNA topoisomerases II alpha and II beta can functionally substitute for yeast TOP2 in chromosome segregation and recombination.

Authors:  S Jensen; C S Redwood; J R Jenkins; A H Andersen; I D Hickson
Journal:  Mol Gen Genet       Date:  1996-08-27

5.  Human cells express two differentially spliced forms of topoisomerase II beta mRNA.

Authors:  S L Davies; J R Jenkins; I D Hickson
Journal:  Nucleic Acids Res       Date:  1993-08-11       Impact factor: 16.971

6.  Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin.

Authors:  Ian G Cowell; Nikolaos Papageorgiou; Kay Padget; Gary P Watters; Caroline A Austin
Journal:  Nucleus       Date:  2011 Jan-Feb       Impact factor: 4.197

7.  The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.

Authors:  H Turley; M Comley; S Houlbrook; N Nozaki; A Kikuchi; I D Hickson; K Gatter; A L Harris
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.

Authors:  K N Meyer; E Kjeldsen; T Straub; B R Knudsen; I D Hickson; A Kikuchi; H Kreipe; F Boege
Journal:  J Cell Biol       Date:  1997-02-24       Impact factor: 10.539

9.  Dynamics of human DNA topoisomerases IIalpha and IIbeta in living cells.

Authors:  Morten O Christensen; Morten K Larsen; Hans Ullrich Barthelmes; Robert Hock; Claus L Andersen; Eigil Kjeldsen; Birgitta R Knudsen; Ole Westergaard; Fritz Boege; Christian Mielke
Journal:  J Cell Biol       Date:  2002-04-01       Impact factor: 10.539

10.  Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.

Authors:  E W Eijdems; M de Haas; A J Timmerman; G P Van der Schans; E Kamst; J de Nooij; G C Astaldi Ricotti; P Borst; F Baas
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.